Parallel Sieve Methods for Generating Prime Numbers

T. Hikita,S. Kawai

Abstract:

What problem does this paper attempt to address?

Decreased Plasma IL‐22 Levels and Correlations with IL‐22‐Producing T Helper Cells in Patients with New‐Onset Systemic Lupus Erythematosus

J. Lin,L. H. Yue,W. Q. Chen

DOI: https://doi.org/10.1111/sji.12135

2014-01-01

Scandinavian Journal of Immunology

Abstract:Interleukin‐22 (IL‐22) and IL‐22‐producing T helper (Th) cells are involved in the pathogenesis of autoimmune diseases. However, the roles of IL‐22 and IL‐22‐producing T helper cells in systemic lupus erythematosus (SLE) remain unclear. Plasma levels of IL‐22 were measured in 41 patients with SLE (19 new‐onset and 22 relapsing patients) and 20 healthy controls by enzyme‐linked immunosorbent assay (ELISA). Meanwhile, the percentages of CD4+IFN‐γ+ (Th1), CD4+IL‐17+ (Th17) and CD4+IFN‐γ−IL‐17− IL‐22+ (Th22) cells in peripheral lymphocytes were determined by flow cytometry, and plasma IL‐22 autoantibodies were detected by ELISA in 19 new‐onset SLE patients and 20 healthy controls. Plasma IL‐22 levels in new‐onset SLE patients were significantly decreased compared with relapsing SLE patients and healthy controls. After treatment with prednisone and hydroxychloroquine, the levels of plasma IL‐22 in new‐onset SLE patients were obviously increased but still lower than healthy controls. There was a positive correlation between plasma IL‐22 levels and the percentages of Th22 cells, but not Th1 and Th17 cells. Moreover, plasma IL‐22 levels as well as peripheral Th17 and Th22 cells correlated with SLE disease activity index (SLEDAI) scores and erythrocyte sedimentation rate (ESR). High frequencies of plasma IL‐22 autoantibodies were detected in new‐onset SLE patients. However, IL‐22 levels did not correlate with IL‐22 autoantibody. Decreased plasma IL‐22 levels and correlation with Th22 cells may be distinct features in new‐onset SLE. Moreover, IL‐22 and Th22 cell correlated with SLE disease activity.
Immune profile alterations of systemic lupus erythematosus patients with infections

Langxian Zhi,Liyang Gu,Lei Tong,Xuesong Liu,Liangjing Lu,Ruru Guo

DOI: https://doi.org/10.1007/s10238-023-01220-z

IF: 4.6

2023-11-10

Clinical and Experimental Medicine

Abstract:This study aimed to elucidate the immune status of systemic lupus erythematosus (SLE) patients with infections. We enrolled 253 SLE patients including 77 patients with infections. Clinical features and immunological parameters were analyzed, with particular reference to neutrophil CD64 (nCD64) expression, myeloid-derived suppressor cells (MDSCs), activated T cells and multiple cytokines. Among the 77 SLE patients with infections, 32 patients (41.56%) developed fever and 20 patients (25.97%) developed serositis, which were higher compared to the non-infection group. A considerably higher level of nCD64 was found in the infection group (4.65 vs 1.01, P < 0.001). In addition, the infection group exhibited higher percentages of total MDSCs (6.99 vs 4.30%, P = 0.003), polymorphonuclear MDSCs (PMN-MDSCs) ( P = 0.032) and monocytic MDSCs (M-MDSCs) ( P = 0.015). T cells were more activated during infections, with an elevated level of IL-2R ( P < 0.001). Specifically, higher percentages of CD4 + CD38 + T cells (55.73 vs 50.17%, P = 0.036), CD8 + HLA-DR + T cells (59.82 vs 47.99%, P < 0.001) and CD8 + CD38 + T cells (68.59 vs 63.90%, P = 0.044) were identified in the infection group. Furthermore, the serum levels of IL-6, IL-8 and IL-10 were elevated in the infection group (all P < 0.001). Higher proportions of neutrophils, CD4 + and CD8 + T cells, and MDSCs were activated during infections in SLE patients. Additionally, the serum cytokines altered during infections, with noticeably elevated levels of IL-6, IL-8 and IL-10. Infections may lead to the amplification of immune alterations in SLE.

medicine, research & experimental
Hormone-refractory and metastatic prostate cancer - palliative radiotherapy.

L. Moser,T. Schubert,W. Hinkelbein

DOI: https://doi.org/10.1159/000139886

Abstract:Prostate cancer progression is commonly manifested by obstructive uropathy, regional lymphatic metastases and hematogenous metastases to the axial skeleton. Radiotherapy is a mainstay in the palliation of symptomatic metastatic prostate cancer and is most often used for the palliation of painful metastatic bone lesions, resulting in a relief of pain in about 80-90% of patients and a reduction of analgesics. In metastatic disease compromising the integrity of the spinal cord or a nerve root, radiotherapy can be used as an urgent intervention to minimize neurological dysfunction and local progression or as an adjunct to surgical decompression. Local progression is often associated with hematuria, ureteric obstruction and perineal discomfort. Symptoms of metastatic lymphadenopathy like leg edema and back discomfort caused by pelvic or paraaortic metastases are related to the immediate anatomic structures affected. Radiotherapy for localized hormone-refractory prostate cancer has an excellent local control rate; nevertheless, the prognosis is poor, the majority of patients failing with distant metastasis within few years. The role of radiotherapy in hormone-refractory and metastatic prostate cancer, considering the patient's individual situation, are presented and discussed.
IFN-γ, should not be ignored in SLE

Wenping Liu,Shumin Zhang,Jibo Wang

DOI: https://doi.org/10.3389/fimmu.2022.954706

IF: 7.3

2022-08-10

Frontiers in Immunology

Abstract:Systemic lupus erythematosus (SLE) is a typical autoimmune disease with a complex pathogenesis and genetic predisposition. With continued understanding of this disease, it was found that SLE is related to the interferon gene signature. Most studies have emphasized the important role of IFN-α in SLE, but our previous study suggested a nonnegligible role of IFN-γ in SLE. Some scholars previously found that IFN-γ is abnormally elevated as early as before the classification of SLE and before the emergence of autoantibodies and IFN-α. Due to the large overlap between IFN-α and IFN-γ, SLE is mostly characterized by expression of the IFN-α gene after onset. Therefore, the role of IFN-γ in SLE may be underestimated. This article mainly reviews the role of IFN-γ in SLE and focuses on the nonnegligible role of IFN-γ in SLE to gain a more comprehensive understanding of the disease.

immunology
THU0036 Discriminating Central Nervous System Infection and Neuropsychiatric Involvement in Patients with Systemic Lupus Erythematosus: A Single-Center Experience

J. Chen,X. Feng,H. Wang,B. Hua,L. Sun

DOI: https://doi.org/10.1136/annrheumdis-2014-eular.2205

IF: 27.973

2014-01-01

Annals of the Rheumatic Diseases

Abstract:Background Despite the improvement of survival rates in SLE patients over the past decades, patients still have higher mortalities compared with the general population that can be largely attributed to uncontrolled disease activities and, most importantly, various kinds of severe infections. Objectives The aim of this study is to identify the clinical differences between central nervous system (CNS) infection and neuropsychiatric lupus (NPSLE) in patients with systemic lupus erythematosus (SLE). Methods Clinical manifestations, laboratory test results and prognoses of 14 SLE patients complicated with various CNS infections, hospitalized in the Drum Tower Hospital in the past seven years, were reviewed and compared with those of 34 concomitantly treated NPSLE patients. The sensitivity and specificity for each variable to identify CNS infection was assessed by receiver operating characteristic (ROC) curves. Results Our study shows that mortality rate was much higher in SLE patients with CNS infection than in NPSLE patients. Compared to NPSLE, those with CNS infection had lower lupus disease activity (SLEDAI), but took higher doses of corticosteroids one month before the occurrence of CNS symptoms. Headache, high fever and vomiting were more common in patients with CNS infections, accompanied with the elevation of C-reactive protein level. Cerebrospinal fluid examination (CSF) examination showed increased leukocytes and protein level but decreased glucose level in patients with CNS infections. Of all the variables, the combination of abnormal CSF test, low SLEDAI score, high fever and high intake of prednisone could best discriminate CNS infection from NPSLE in SLE patients (AUC=0.999, p=4.48x10–19). Conclusions We conclude that for SLE patients who have CNS symptoms, low SLE disease activity but high intake of corticosteroids, together with abnormal CSF and high fever, may suggest the existence of CNS infection. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.2205
Systemic lupus erythematosus and infections

B K Singh,S Singh

DOI: https://doi.org/10.4081/reumatismo.2020.1303

2020-11-19

Reumatismo

Abstract:Systemic lupus erythematosus (SLE) is an inflammatory and multi-systemic autoimmune disorder, characterized by an uncontrolled auto-reactivity of B and T lymphocytes, leading to the production of autoantibodies against self-directed antigens and tissue damage. The life expectancy in patients with SLE has improved tremendously in the last two decades, but the mortality rates still remain three times greater compared to those of the general population. Despite increased awareness and improved management, infections remain a major source of morbidity, mortality, hospitalization, and death in patients with SLE. The infections in SLE patients widely range from opportunistic to common bacterial and viral infections with typical or atypical presentations. Moreover, SLE patients exhibit an increased susceptibility to hospital-acquired infections. Factors associated with increased risk of infections include high disease activity, specific immune dysregulation, drug-induced immune deficiency, and organ failure with irreversible damage. Furthermore, immunosuppressive agents may make patients more susceptible to opportunistic infections. A big challenge faced by physicians in these patients is to distinguish between infections and flares of SLE, as infections may mimic them, leading to predicament in diagnosis and appropriate management. Immunosuppression used to treat severe flares of lupus can have catastrophic complications in patients with active infections. There is an urgent need for biomarkers to make an accurate differential diagnosis in this situation. In spite of increased understanding of SLE, many questions remain unanswered. Further research is needed to determine specific immune dysregulation underlying the increased susceptibility to specific infections, predictors of infection in SLE such as genetic markers, and biomarkers that discriminate between disease activity and active infections. Also, measures must be evaluated appropriately to prevent infections, and their complications in SLE.
357 Increased peripheral cd8 t cell responses in sle by low-dose il-2 treatment

R Zhang,J He,X Sun,C Li,Y Gan,Y Zou,Z Li

DOI: https://doi.org/10.1136/lupus-2017-000215.357

2017-01-01

Abstract:Background and aims CD8 T cell responses to viral pathogens is crucial for the prompt resolution of acute infections. SLE patients are more likely to have infections due to long-term glucocorticoid and immunosuppressive agent intake. The present study is to evaluate the potential anti-infection effect of low-dose IL-2 in SLE patients. Methods Peripheral blood mononuclear cells from nine refractory SLE patients and 9 health controls (HCs). The disease activities were evaluated by rheumatologist. The frequencies of T cell subsets were assayed by flow cytometry. Virus-specific CD8 T cells responses were determined based on TNF-a IFN-g and Granzyme B producing CD8 T cells upon CMV-EBV-Flu(CEF) viral peptide pool stimulation. Results Most patients showed good clinical responses after low-dose IL-2 treatment (7 out of 9). Clinical improvement was observed with SIR-4 response (6 out of 9), improved complement 3 and 4 serum level (9 out of 9) and decreased anti-ds-DNA serum level (8 out of 9). Functional profiling of CD8 T cells in low-dose IL-2 treated patients revealed increased frequencies of CEF viral peptide specific TNF-a + and Granzyme-B + CD8 T cells. Moreover, these patients showed stronger antigen-specific response demonstrated by an increased stimulated/non-stimulate TNF-a-producing CD8 T cells proliferation fold. Compared with HC, SLE patients showed significantly lower frequencies of CEF specific Granzyme-B producing CD8 T cell, and low-dose IL-2 significantly increased the frequency of these Granzyme-B + CD8 T cells in SLE patients. Conclusions Virus-specific antigen-specific CD8 T cell response could be enhanced upon this treatment which might be potentially valuable in anti-infection in SLE.
Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus

V Caneparo,T Cena,M De Andrea,V Dell'oste,P Stratta,M Quaglia,A Tincani,L Andreoli,S Ceffa,M Taraborelli,C Magnani,S Landolfo,M Gariglio

DOI: https://doi.org/10.1177/0961203313484978

IF: 2.858

Lupus

Abstract:Objective: Several studies have shown the presence of anti-IFI16 antibodies in systemic lupus erythematosus (SLE), Sjögren Syndrome (SjS), systemic sclerosis (SSc) and other autoimmune diseases. However, the significance of anti-IFI16 antibodies in SLE has not been fully characterized. The aim of this study was to investigate associations between anti-IFI16 antibodies and clinical and serologic parameters of SLE. Methods: An enzyme-linked immunosorbent assay (ELISA) kit was used to measure anti-IFI16 antibodies in the sera of 168 SLE patients, 46 patients with any type of primary glomerulonephritis (GN) and 182 healthy controls (HCs). Associations between anti-IFI16 antibodies and clinical and serologic parameters of SLE were statistically evaluated using both univariate and multivariate analysis. Results: Significantly higher anti-IFI16 titres were observed in SLE patients compared to both non-SLE GN and HCs (median levels: 270.1 U/ml vs 132.1 U/ml, p = 0.001, and 52.9 U/ml, p < 0.0001, respectively). With cut-off levels corresponding to the 95th percentile of the control population (113 U/ml), 63% of the SLE patients tested positive for anti-IFI16 autoantibodies, compared to just 24% of patients with primary non-SLE GN and 5% of HCs. The presence of anti-IFI16 antibodies inversely correlated with proteinuria (univariate analysis) and C3 hypocomplementaemia (univariate and multivariate analyses). Conclusions: The inverse correlations observed between anti-IFI16 positivity, proteinuria and C3 hypocomplementaemia suggest that anti-IFI16 antibodies do not contribute to renal inflammation in SLE; indeed they may even prevent complement consumption. Anti-IFI16 antibodies hold the potential to serve as a new biomarker of disease activity in SLE.
Infection with Opportunistic Bacteria Triggers Severe Pulmonary Inflammation in Lupus-Prone Mice

Wenchao Li,Weiwei Chen,Saisai Huang,Xiaojun Tang,Genhong Yao,Lingyun Sun

DOI: https://doi.org/10.1155/2019/1701367

2019-01-01

Mediators of Inflammation

Abstract:Infection is a common cause of hospitalization and mortality in patients with systemic lupus erythematosus (SLE). How the underlying immune dysfunctions affect the antimicrobial immunity remains largely unknown. In the present study, employing the pulmonary infection model, we determined the antimicrobial defence of lupus-prone mice. After infecting with opportunistic bacterium Haemophilus influenzae (Hi), lupus-prone mice (B6/lpr) exhibited inefficient bacterial elimination and recovered slowly. They generated severer inflammation at the early stage of infection, as excessive accumulation of neutrophils and enhanced production of proinflammatory cytokines were observed in the lung. In addition, a large number of apoptotic cells were detected in the lungs of B6/lpr mice. For adaptive immune responses, B6/lpr mice were capable to generate enough protective Hi-specific Th17 cells. They evoked stronger Hi-specific γδ T17 response in both lungs and spleens. Unexpectedly, both CD4 and γδ T cells from lupus-prone mice showed deficiency in IFN-γ production. For humoral immune responses, compared with those of WT mice, the concentrations of Hi-specific IgA, IgM, and IgG, especially IgG, were significantly higher in the B6/lpr mice. Our findings suggest that lupus mice are capable to generate antibacterial immune responses; however, the overwhelming inflammation and overactivated immune responses increase the severity of infection.
Identification and Clinical Correlation Analysis of IFI44 in Systemic Lupus Erythematosus Combined with Bioinformatics and Immune Infiltration Analysis

Yuan Wang,Chengfeng Ma,Zhanbing Ma,Mengyi Yang,Jing Pu,Xiuhui Ma,Xi Wu,Liang Peng,Zhenghao Huo,Jie Dang

DOI: https://doi.org/10.2147/JIR.S419880

IF: 4.5

2023-08-02

Journal of Inflammation Research

Abstract:Yuan Wang, 1– 3 Chengfeng Ma, 1, 2 Zhanbing Ma, 1, 2 Mengyi Yang, 1, 2 Jing Pu, 1, 2 Xiuhui Ma, 1, 2 Xi Wu, 1, 2 Liang Peng, 1, 2 Zhenghao Huo, 1, 2, &ast Jie Dang 1, 2, &ast 1 School of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China; 2 Key Laboratory of Fertility Preservation and Maintenance of the Ministry of Education, Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China; 3 Department of Dermatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jie Dang; Zhenghao Huo, Department of Medical Genetics and Cell Biology, School of Basic Medicine, Ningxia Medical University, 1160 Shengli Street, Yinchuan, Ningxia, 750001, People's Republic of China, Tel/Fax +86-951-6980049, Email Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can cause systemic damage to multiple organs. This study aims to analyze the value and function of IFI44 in the diagnosis and pathology of SLE by bioinformatics and immune infiltration analysis. Patients and Methods: GSE49454 and GSE65391 of SLE were obtained from the GEO dataset, and R software was employed to identify DEGs and investigate their functions. The PPI network was utilized to identify hub genes associated with SLE. CIBERSORT was used to assess differences in immune cell infiltration in SLE patients and controls. ROC curve analysis was performed to evaluate the diagnostic value of IFI44 in SLE. The expression of IFI44 in PBMCs was detected by RT-qPCR, and the correlation between IFI44 expression and SLE-related clinical indicators was analyzed. Results: A total of 65 DEGs were identified from the GSE49454 and GSE65391 databases. Through PPI analysis, IFI44 and RSAD2 were identified as significantly aberrantly expressed in SLE patients. SLE patients and controls showed a significant difference in the proportion of immune cell infiltration. IFI44 expression was positively correlated with activated DCs, monocytes, PCs, neutrophils, and activated memory CD4 + T cells, while negatively correlated with M0 and CD8 + T cells. The expression of IFI44 was significantly higher in SLE patients ( P < 0.01), especially in male patients ( P =0.0376). ROC curve analysis demonstrated that IFI44 had a high diagnostic value for SLE. Correlation analysis indicated that IFI44 expression was correlated with levels of RBC, HGB, HCT, IgA, ESR, UPRO, C3, C4, and ENA in SLE patients. Conclusion: IFI44 may play a role in the pathogenesis of SLE by influencing the immune microenvironment of SLE patients, and thus has the potential to serve as a diagnostic marker and therapeutic target for SLE. Keywords: systemic lupus erythematosus, IFI44 , bioinformatics, immune cell infiltration, sexual dimorphism Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system attacks the body's own tissues, causing widespread inflammation and tissue damage in affected organs. SLE is most commonly diagnosed between the ages of 20 and 30, with a male-to-female ratio of 1:9. 1 Incidence and prevalence of SLE vary widely among different geographic regions, with the highest reported rates in North America and the lowest in Africa and Australia. 2 Although the exact cause of SLE is not well understood, it is known to involve a complex interaction of environmental, genetic, and epigenetic factors. 3 Treatment for SLE patients depends on the presentation and activity of the disease, with the ultimate goal of achieving remission or reducing disease activity through various immunoregulatory and immunosuppressive therapies. Strong activation of complement and production of type I interferon (IFN) are key factors in the pathogenesis of SLE. Type I IFN promote immune response activation to nucleic acids and their associated proteins, resulting in autoantibody production, immune complex formation, and organ inflammation. 4 Patients with elevated type I IFN signatures are more likely to develop lupus nephritis, which is inflammation of the kidneys that can lead to impaired function and kidney failure. 5 Several cross-sectional studies have shown that IFN markers are associated with disease activity and severe SLE involving the kidneys, hematopoietic system, and nervous -Abstract Truncated-

immunology
The Expression of Peripherial Blood Neutrophil CD64 in Systemic Lupus Erythematosus with Infection or Disease Activation

Xu-yan Yang,Jin Lin,You-ming Li

DOI: https://doi.org/10.3760/j.issn:0578-1426.2003.12.010

2003-01-01

Abstract:OBJECTIVE:To explore the significance of expression of peripheral blood neutrophil CD(64) to distinguish infection from disease activation in systemic lupus erythematosus (SLE).METHODS:19 patients with infection and 46 patients with non-infection in 65 SLE patients were studied. The levels of peripheral blood neutrophil CD(64) were measured by flow cytometry.RESULTS:The levels of peripheral blood neutrophil CD(64) in SLE infection patients were [(7.8 +/- 2.1)%], which were significantly higher than that of non-infection group [(3.2 +/- 1.4)%] and healthy control [(3.0 +/- 1.1)%, P > 0.05]. However, there were no significance between the levels of non-infection group and healthy control (P > 0.05). There were no significance between the levels of CD(64) of disease activation and silence group and non-infection group (P > 0.05). In SLE infection group, the levels of CD(64) expression in patients with Gram-negative [(9.2 +/- 1.6)%] were compared with [(7.2 +/- 2.2)%] those with Gram-positive. The differences were not significant (P > 0.05). The levels of CD(64) of SLE patients with infection were decreased by treatment with antibiotics. The correlation of the levels of CD(64) with anti-dsDNA, C(3), ESR, CRP, SLE-disease activity index and IFANA were not found (respectively r = 0.104, P = 0.409; r = -0.125, P = 0.322; r = -0.138, P = 0.274; r = 0.228, P = 0.068; r = 0.204, P = 0.310; r = -0.213, P = 0.089).CONCLUSION:The levels of peripheral blood neutrophil CD(64) may help us distinguish infection from disease activation in SLE.
Association Of Increased Interferon-Inducible Gene Expression With Disease Activity And Lupus Nephritis In Patients With Systemic Lupus Erythematosus

Xuebing Feng,Hui Wu,Jennifer M. Grossman,Punchong Hanvivadhanakul,John D. Fitzgerald,Grace S. Park,Xin Dong,Weiling Chen,Michelle H. Kim,Haoling H. Weng,Daniel E. Furst,Alan Gorn,Maureen Mcmahon,Mihaela Taylor,Ernest Brahn,Bevra H. Hahn,Betty P. Tsao

DOI: https://doi.org/10.1002/art.22044

2006-01-01

Abstract:Objective. To study 5 type I interferon (IFN)-inducible genes (LY6E, OAS1, OASL, MX1, and ISG15) in patients with systemic lupus erythematosus (SLE) and to correlate expression levels with disease activity and/or clinical manifestations.Methods. Peripheral blood cells were obtained from 48 SLE patients, 48 normal controls, and 22 rheumatic disease controls, and total RNA was extracted and reverse transcribed into complementary DNA. Gene expression levels were measured by real-time polymerase chain reaction, standardized to a housekeeping gene, and summed to an IFN score. Disease activity was determined by the Safety of Estrogens in Lupus Erythematosus: National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) composite.Results. Each gene was highly expressed in SLE patients compared with normal controls (P <= 0.0003) or disease controls (P <= 0.0008 except for MX1). IFN scores were positively associated with the SELENA-SLEDAI instrument score (P = 0.001), the SELENA-SLEDAI flare score (P = 0.03), and the physician's global assessment score (P = 0.005). Compared with patients without nephritis, lupus nephritis patients had higher IFN scores (overall P < 0.0001), especially during active renal disease. IFN scores were weakly associated with neurologic manifestations. Elevated IFN scores were positively associated with the current presence of anti-double-stranded DNA (anti-dsDNA) antibodies (P = 0.007) or hypocomplementemia (P = 0.007). LY6E expression levels distinguished active from inactive lupus nephritis (P = 0.02) and were positively associated with proteinuria (P = 0.009).Conclusion. The 5 IFN-inducible genes were highly expressed in SLE patients, and increased levels were correlated with disease activity defined by several methods. IFN scores, or LY6E levels, were elevated in lupus nephritis patients, especially during active renal disease, and in patients with anti-dsDNA antibody positivity and hypocomplementemia. IFN scores, or LY6E levels, may be useful as a biomarker for lupus nephritis therapy.
Increased interferon-inducible gene expression, an useful marker in the diagnosis and disease activity evaluation of systemic lupus erythematosus

Ji-yun ZHANG,Jing HUANG,Rong-liang LI,Ling-yun SUN,Xue-bing FENG

DOI: https://doi.org/10.3760/cma.j.issn.1007-7480.2010.12.002

2010-01-01

Abstract:Objective To study the role of the expression levels of 5 type Ⅰ interferon (IFN)-inducible genes (LY6E, OAS1, OASL, MX1, and ISG15) in the diagnosis and disease activity evaluation of systemic lupus erythematosus (SLE). Methods Peripheral blood was obtained from 68 SLE patients, 50 patients with other connective tissue diseases and 26 normal controls, and total RNA was extracted and reverse transcribed into complementary DNA. Real-time PCR technique was used to determine gene expressions at transcription level. An IFN score for each individual was calculated according to the expression of 5 1FN genes. Comparisons of gene expression and IFN score were made among groups. The genes expression levels in patients with SLE were analyzed using receiver operative characteristic curve. The association between IFN scores and disease activity, as assessed by the SLEDAI scores and 24 h proteinuria, was analyzed using Spearman correlation analyses. Results ① The expression levels of MX1, OASL, OAS1, ISG15 and LY6E mRNA in SLE patients were significantly increased as compared with normal controls and disease controls (P all＜0.01 ).② IFN scores in SLE patients (17.9±29.1) were significantly increased as compared with normal controls (0±3.3)and disease controls (3.0±8.1) (P all＜0.01 ). ③ IFN scores area under the ROC curve (AUCROC) was 0.846. When The IFN scores reached 2.56, its sensitivity and specificity for the diagnosis of SLE were 93.1%and 78.3%, respectively. ④ Levels of IFN score was positively correlated with SLEDAI scores (r=0.256,P＜0.05) and 24 h proteinuria (r=0.337, P＜0.05). Conclusion The 5 IFN-inducible genes are highly expressed in SLE patients. IFN score level is valuable for the diagnosis of SLE and a high IFN score is usually associated with an elevated disease activity.
Risk factors for initial and recurrent severe infections in first hospitalized patients with systemic lupus erythematosus: A retrospective study of a Chinese cohort

Ying Zhu,Kexin Zhu,Xueyi Zhang,Zhijie Qian,Qingqing Guo,Xuefeng Xu,Genhong Yao,Xiaojun Tang,Dandan Wang,Huayong Zhang,Xuebing Feng,Ziyi Jin,Lingyun Sun

DOI: https://doi.org/10.1111/1756-185x.15131

2024-04-03

International Journal of Rheumatic Diseases

Abstract:Abstract Objective To evaluate the incidence and associated factors of initial and recurrent severe infections in hospitalized patients with systemic lupus erythematosus (SLE). Methods SLE patients that first hospitalized between 2010 and 2021 were studied retrospectively and divided into SLE with and without baseline severe infection groups. The primary outcome was the occurrence of severe infection during follow‐up. Cox regression models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for initial and recurrent severe infections. Results Among 1051 first hospitalized SLE patients, 164 (15.6%) had severe infection on admission. During a median follow‐up of 4.1 years, 113 (10.8%) patients reached severe infection outcomes, including 27 with reinfection and 86 with initial severe infection (16.5% vs. 9.7%, p = .010). Patients with baseline severe infection had a higher cumulative incidence of reinfection ( p = .007). After adjusting for confounding factors, renal involvement, elevated serum creatinine, hypoalbuminemia, cyclophosphamide, and mycophenolate mofetil treatment were associated with an increased risk of severe infection, especially initial severe infection. Low immunoglobulin, anti‐dsDNA antibody positivity, and cyclophosphamide use significantly increased the risk of recurrent severe infection, with adjusted HR (95% CI) of 3.15 (1.22, 8.14), 3.60 (1.56, 8.28), and 2.14 (1.01, 5.76), respectively. Moreover, baseline severe infection and low immunoglobulin had a multiplicative interaction on reinfection, with adjusted RHR (95% CI) of 3.91 (1.27, 12.09). Conclusion In this cohort of SLE, patients with severe infection had a higher risk of reinfection, and low immunoglobulin, anti‐dsDNA antibody positivity, and cyclophosphamide use were independent risk factors for recurrent severe infection.

rheumatology
A dynamic approach to the Shapley value based on associated games

Yan-An Hwang,Jie-Hau Li,Yaw-Hwa Hsiao

DOI: https://doi.org/10.1007/s00182-005-0217-5

2005-11-01

International Journal of Game Theory

Abstract:
[Evaluating Type I Interferon-Inducible Gene Expression in Patients with Systemic Lupus Erythematosus.].

Jing Huang,Rong-Liang Li,Li-Na Zhu,Ling-Yun Sun,Xue-Bing Feng

DOI: https://doi.org/10.3760/cma.j.issn.0578-1426.2010.01.013

2010-01-01

Abstract:OBJECTIVE:To explore the expression levels of interferon-inducible genes in patients with systemic lupus erythematosus (SLE), and to validate these gene expressions as potential biomarkers for the differentiation of disease flare and infection.METHODS:Peripheral blood was obtained from 48 SLE, 16 rheumatoid arthritis (RA) patients and 26 normal controls, and total RNA was extracted and reverse transcribed into complementary DNA. Real-time PCR technique was used to determine the gene expressions of MX1, OASL, OAS1, ISG15 and LY6E at transcription level. Univariate logistic regression analysis and multivariate conditional logistic regression model were applied to analyze 5 related factors for infection or activity.RESULTS:(1) The expression levels of MX1, OASL, OAS1, ISG15, and LY6E mRNA in SLE patients were significantly increased as compared with normal controls (P all < 0.01), while the expression levels of OASL, OAS1, ISG15 and LY6E mRNA in SLE patients were also higher than those in RA patients (P all < 0.05). (2) There were no significant difference between male and female patients of the 5 gene expression in SLE patients. (3) By logistic regression analysis, ISG15 and LY6E were independent risk factors for active SLE patients (P < 0.01), OASL expression was an independent risk factor for SLE patients with infection (P = 0.003).CONCLUSION:All the 5 interferon inducible genes are highly expressed in SLE patients, in which ISG15 and LY6E are independently associated with disease flare, while OASL may be helpful for the evaluation of infection in SLE patients.
Elevated Serum Interleukin-35 Is Associated With Disease Activity In Patients With Systemic Lupus Erythematosus

Chun Li,Na Liu,Huaqun Zhu,Liling Xu,Rong Mu

DOI: https://doi.org/10.1111/1756-185X.13128

2017-01-01

International Journal of Rheumatic Diseases

Abstract:Dear Editor, Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a wide variety of presenting features. Many studies have suggested cytokines are involved in the pathogenesis of SLE.1-4 Interleukin (IL)-35, a heterodimeric cytokine composed of the subunits EBI3 and p35, was recently identified as a new member of the IL-12 cytokine family.5 The role of IL-35 remains controversial in inflammatory diseases. Some studies have shown its anti-inflammatory properties given its effect on Treg, regulator B cells and associated cytokines in inflammatory bowel disease, collagen-induced arthritis or other autoimmune diseases.6-8 In contrast, IL-35 enhanced the inflammatory response in Lyme arthritis9 and IL-35 gene therapy exacerbates experimental rheumatoid arthritis in mice.10 The expression and significance of IL-35 in patients with SLE is still obscure. Several studies have shown that the level of IL-35 was decreased and the percentage of CD4+ EBI3+ T cells were also significantly decreased in patients with active SLE.11, 12 Another study showed that plasma IL-35 and soluble gp130 levels were significantly higher in patients with severe SLE.13 We conducted this study to investigate the IL-35 level in patients with SLE and their potential association with clinical manifestations and disease activity. We enrolled 145 patients with SLE (133 females and 12 males, mean age 35.6 ± 13.9 years) and 69 age- and sex-matched healthy volunteers without diseases. The protocol for the study was approved by the Ethics Committee of Peking University People's Hospital (FWA00001384). Clinical and laboratory features of SLE patients were recorded. Serum levels of IL-35 were measured by enzyme-linked immunosorbent assay according to the manufacturer's protocol (USCN Life Science, Wuhan, China). The levels of serum IL-35 were significantly higher in patients with SLE than in healthy controls (125.7 ± 110.5 vs. 19.1 ± 45.4, t = 10.050, P = 0.0000) (Fig. 1). The levels of IL-35 were significantly higher in SLE patients with SLE Disease Activity Index (SLEDAI) scores ≥ 8 than patients with SLEDAI score < 8 (85.29 vs. 54.57, Z = −4.314, P = 0.000). The levels of serum IL-35 were correlated with anti-double-stranded DNA antibodies (r = 0.214, P = 0.010) and SLEDAI scores(r = 0.326, P = 0.000) (Fig. 2). The levels of serum IL-35 decreased significantly in accordance with disease activity after treatment in a subgroup of 19 patients with SLE (Fig. 3). Serum levels of IL-35 were associated with photosensitivity (115.5 ± 96.2 vs. 194.1 ± 170.5, t = −2.945, P = 0.004), arthritis (109.8 ± 104.5 vs. 161.4 ± 118.5, t = −2.636, P = 0.009) and fever (109.3 ± 103.9 vs. 161.3 ± 119.1, t = −2.672, P = 0.008) (Table 1). We could see that IL-35 levels were lower in SLE patients with antiphospholipid syndrome (APS) than those without APS, but there was no statistical difference between these two groups. In conclusion, we demonstrate circulating IL-35 is significantly higher than healthy controls and associate with disease activity in SLE. IL-35 might be involved in the pathogenesis of SLE. This work was supported by the National Nature Science Foundation of China (grant no. NSFC.81202297). The authors have no conflicts of interest to declare.
Identification of Interferon-Inducible Genes As Diagnostic Biomarker for Systemic Lupus Erythematosus

Xuebing Feng,Jing Huang,Yan Liu,Lihui Xiao,Dandan Wang,Bingzhu Hua,Betty P. Tsao,Lingyun Sun

DOI: https://doi.org/10.1007/s10067-014-2799-4

2014-01-01

Clinical Rheumatology

Abstract:The identification of biomarkers helps to perform early diagnosis, thus benefits the outcome of patients with systemic lupus erythematosus (SLE), in which delayed treatment has been proposed as an independent adverse prognostic factor. In this study, we assessed the values of expression levels of five type I interferon (IFN)-inducible genes (LY6E, OAS1, OASL, MX1, and ISG15) and total IFN score for the diagnosis of SLE. Quantitative real-time PCR was applied to determine gene expressions at transcription level in peripheral blood from 69 SLE patients, 42 patients with other connective tissue diseases, and 26 normal controls. Expressions of five genes and IFN score, calculated according to the expressions of IFN-inducible genes, were all significantly increased in SLE patients compared to those in normal subjects and disease controls. IFN score was not related to age, gender, and the dose of steroids, but weakly correlated with SLE disease activity index. None of the gene expression was associated with concomitant infection status or elevated antibodies against Epstein–Barr (EB) virus in SLE. Both modified IFN score (calculated by the expression of three major IFN-inducible genes) and LY6E level showed good diagnostic accuracy in discriminating between SLE patients and disease controls as well as normal subjects (area under the receiver operating characteristic curve was 0.812 and 0.815, respectively), with 70–80 % specificity and 70–80 % sensitivity at the cutoff of 2.37 and 3.23. In conclusion, high IFN-inducible gene expression is constitutional for SLE patients. The modified IFN score or the LY6E level alone may serve as good biomarkers for SLE diagnosis.
Optimal Selection of IFN-α-Inducible Genes to Determine Type I Interferon Signature Improves the Diagnosis of Systemic Lupus Erythematosus

Veronique Demers-Mathieu

DOI: https://doi.org/10.3390/biomedicines11030864

IF: 4.757

2023-03-12

Biomedicines

Abstract:Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies specific to self-molecules in the nucleus, cytoplasm, and cell surface. The diversity of serologic and clinical manifestations observed in SLE patients challenges the development of diagnostics and tools for monitoring disease activity. Elevated type I interferon signature (IFN- I) in SLE leads to dysregulation of innate and adaptive immune function, resulting in autoantibodies production. The most common method to determine IFN-I signature is measuring the gene expression of several IFN-α-inducible genes (IFIGs) in blood samples and calculating a score. Optimal selection of IFIGs improves the sensitivity, specificity, and accuracy of the diagnosis of SLE. We describe the mechanisms of the immunopathogenesis of IFN-I signature (IFNα production) and its clinical consequences in SLE. In addition, we explore the association between IFN-I signature, the presence of autoantibodies, disease activity, medical therapy, and ethnicity. We discuss the presence of IFN-I signature in some patients with other autoimmune diseases, including rheumatoid arthritis, systemic and multiple sclerosis, Sjogren's syndrome, and dermatomyositis. Prospective studies are required to assess the role of IFIG and the best combination of IFIGs to monitor SLE disease activity and drug treatments.
Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells

Jennie A Hamilton,Qi Wu,PingAr Yang,Bao Luo,Shanrun Liu,Jun Li,Alexa L Mattheyses,Ignacio Sanz,W Winn Chatham,Hui-Chen Hsu,John D Mountz,Jennie A. Hamilton,Alexa L. Mattheyses,W. Winn Chatham,John D. Mountz

DOI: https://doi.org/10.4049/jimmunol.1800791

2018-09-10

The Journal of Immunology

Abstract:In systemic lupus erythematosus (SLE), type I IFNs promote induction of type I IFN-stimulated genes (ISG) and can drive B cells to produce autoantibodies. Little is known about the expression of distinct type I IFNs in lupus, particularly high-affinity IFN-β. Single-cell analyses of transitional B cells isolated from SLE patients revealed distinct B cell subpopulations, including type I IFN producers, IFN responders, and mixed IFN producer/responder clusters. Anti-Ig plus TLR3 stimulation of SLE B cells induced release of bioactive type I IFNs that could stimulate HEK-Blue cells. Increased levels of IFN-β were detected in circulating B cells from SLE patients compared with controls and were significantly higher in African American patients with renal disease and in patients with autoantibodies. Together, the results identify type I IFN-producing and -responding subpopulations within the SLE B cell compartment and suggest that some patients may benefit from specific targeting of IFN-β.

Parallel Sieve Methods for Generating Prime Numbers

Decreased Plasma IL‐22 Levels and Correlations with IL‐22‐Producing T Helper Cells in Patients with New‐Onset Systemic Lupus Erythematosus

Immune profile alterations of systemic lupus erythematosus patients with infections

Hormone-refractory and metastatic prostate cancer - palliative radiotherapy.

IFN-γ, should not be ignored in SLE

THU0036 Discriminating Central Nervous System Infection and Neuropsychiatric Involvement in Patients with Systemic Lupus Erythematosus: A Single-Center Experience

Systemic lupus erythematosus and infections

357 Increased peripheral cd8 t cell responses in sle by low-dose il-2 treatment

Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Infection with Opportunistic Bacteria Triggers Severe Pulmonary Inflammation in Lupus-Prone Mice

Identification and Clinical Correlation Analysis of IFI44 in Systemic Lupus Erythematosus Combined with Bioinformatics and Immune Infiltration Analysis

The Expression of Peripherial Blood Neutrophil CD64 in Systemic Lupus Erythematosus with Infection or Disease Activation

Association Of Increased Interferon-Inducible Gene Expression With Disease Activity And Lupus Nephritis In Patients With Systemic Lupus Erythematosus

Increased interferon-inducible gene expression, an useful marker in the diagnosis and disease activity evaluation of systemic lupus erythematosus

Risk factors for initial and recurrent severe infections in first hospitalized patients with systemic lupus erythematosus: A retrospective study of a Chinese cohort

A dynamic approach to the Shapley value based on associated games

[Evaluating Type I Interferon-Inducible Gene Expression in Patients with Systemic Lupus Erythematosus.].

Elevated Serum Interleukin-35 Is Associated With Disease Activity In Patients With Systemic Lupus Erythematosus

Identification of Interferon-Inducible Genes As Diagnostic Biomarker for Systemic Lupus Erythematosus

Optimal Selection of IFN-α-Inducible Genes to Determine Type I Interferon Signature Improves the Diagnosis of Systemic Lupus Erythematosus

Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells